Meridian Bioscience, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding, Public
- Established
- 1977-01-01
- Employees
- 515
- Market Cap
- -
Clinical Trials
27
Active:0
Completed:22
Trial Phases
5 Phases
Phase 1:1
Phase 2:5
Phase 3:4
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Not Applicable
7 (38.9%)Phase 2
5 (27.8%)Phase 3
4 (22.2%)Phase 1
1 (5.6%)Phase 4
1 (5.6%)Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol
Completed
- Conditions
- Streptococcus Pneumoniae InfectionLegionella Pneumophila Serogroup 1 Infection
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Meridian Bioscience, Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT05681156
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.
Not Applicable
- Conditions
- Carbapenem-Resistant Enterobacteriaceae
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Meridian Bioscience, Inc.
- Target Recruit Count
- 1200
- Registration Number
- NCT03680898
- Locations
- 🇺🇸
Indiana University and Purdue University Institutions, Indianapolis, Indiana, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇨🇦Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex, Toronto, Ontario, Canada
Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
Completed
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Meridian Bioscience, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT03611101
- Locations
- 🇺🇸
Spring Gastroenterology, Humble, Texas, United States
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
Terminated
- Conditions
- Decompensated Cirrhosis
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Meridian Bioscience, Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT03462576
- Locations
- 🇺🇸
Florida Digestive Health Specialists Research Institute, Lakewood Ranch, Florida, United States
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
Completed
- Conditions
- CirrhosisNASH - Nonalcoholic SteatohepatitisPortal Hypertension
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Meridian Bioscience, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT03439189
- Locations
- 🇫🇷
Hopital Beaujon, Clichy, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found